Glutamine metabolism in breast cancer and possible therapeutic targets

被引:43
作者
Li, Shiqi [1 ]
Zeng, Hui [2 ]
Fan, Junli [1 ]
Wang, Fubing [1 ]
Xu, Chen [1 ]
Li, Yirong [1 ]
Tu, Jiancheng [1 ]
Nephew, Kenneth P. [3 ]
Long, Xinghua [1 ]
机构
[1] Wuhan Univ, Zhongnan Hosp, Dept Lab Med, Wuhan, Peoples R China
[2] Hangzhou Ninth Peoples Hosp, Ctr Clin Lab, Hangzhou, Peoples R China
[3] Indiana Univ, Med Sci Program, Bloomington, IN 47405 USA
关键词
Breast cancer; Glutamine metabolism; Ferroptosis; Immune microenvironment; Amino acid transporters; Glutaminase; AMINO-ACID TRANSPORTER; AMMONIA-INDUCED AUTOPHAGY; MITOCHONDRIAL METABOLISM; TUMOR-GROWTH; EXPRESSION; APOPTOSIS; RECEPTOR; PATHWAY; ASPARAGINE; INHIBITION;
D O I
10.1016/j.bcp.2023.115464
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cancer is characterized by metabolic reprogramming, which is a hot topic in tumor treatment research. Cancer cells alter metabolic pathways to promote their growth, and the common purpose of these altered metabolic pathways is to adapt the metabolic state to the uncontrolled proliferation of cancer cells. Most cancer cells in a state of nonhypoxia will increase the uptake of glucose and produce lactate, called the Warburg effect. Increased glucose consumption is used as a carbon source to support cell proliferation, including nucleotide, lipid and protein synthesis. In the Warburg effect, pyruvate dehydrogenase activity decreases, thereby disrupting the TCA cycle. In addition to glucose, glutamine is also an important nutrient for the growth and proliferation of cancer cells, an important carbon bank and nitrogen bank for the growth and proliferation of cancer cells, providing ribose, nonessential amino acids, citrate, and glycerin necessary for cancer cell growth and proliferation and compensating for the reduction in oxidative phosphorylation pathways in cancer cells caused by the Warburg effect. In human plasma, glutamine is the most abundant amino acid. Normal cells produce glutamine via glutamine synthase (GLS), but the glutamine synthesized by tumor cells is insufficient to meet their high growth needs, resulting in a "glutamine-dependent phenomenon." Most cancers have an increased glutamine demand, including breast cancer. Metabolic reprogramming not only enables tumor cells to maintain the reduction-oxidation (redox) balance and commit resources to biosynthesis but also establishes heterogeneous metabolic phenotypes of tumor cells that are distinct from those of nontumor cells. Thus, targeting the metabolic differences between tumor and nontumor cells may be a promising and novel anticancer strategy. Glutamine metabolic compartments have emerged as promising candidates, especially in TNBC and drug-resistant breast cancer. In this review, the latest discoveries of breast cancer and glutamine metabolism are discussed, novel treatment methods based on amino acid transporters and glutaminase are discussed, and the relationship between glutamine metabolism and breast cancer metastasis, drug resistance, tumor immunity and ferroptosis are explained, which provides new ideas for the clinical treatment of breast cancer.
引用
收藏
页数:14
相关论文
共 165 条
  • [1] SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer
    Alfarsi, Lutfi H.
    El Ansari, Rokaya
    Craze, Madeleine L.
    Mohammed, Omar J.
    Masisi, Brendah K.
    Ellis, Ian O.
    Rakha, Emad A.
    Green, Andrew R.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (02) : 317 - 331
  • [2] Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer
    Alfarsi, Lutfi H.
    El-Ansari, Rokaya
    Craze, Madeleine L.
    Masisi, Brendah K.
    Mohammed, Omar J.
    Ellis, Ian O.
    Rakha, Emad A.
    Green, Andrew R.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (04)
  • [3] Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance
    Althobiti, Maryam
    Aleskandarany, Mohammed A.
    Joseph, Chitra
    Toss, Michael
    Mongan, Nigel
    Diez-Rodriguez, Maria
    Nolan, Christopher C.
    Ashankyty, Ibraheem
    Ellis, Ian O.
    Green, Andrew R.
    Rakha, Emad A.
    [J]. HISTOPATHOLOGY, 2018, 73 (06) : 887 - 896
  • [4] From Krebs to clinic: glutamine metabolism to cancer therapy
    Altman, Brian J.
    Stine, Zachary E.
    Dang, Chi V.
    [J]. NATURE REVIEWS CANCER, 2016, 16 (10) : 619 - 634
  • [5] Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss
    Andrade-Vieira, Rafaela
    Goguen, Donna
    Bentley, Heidi A.
    Bowen, Chris V.
    Marignani, Paola A.
    [J]. ONCOTARGET, 2014, 5 (24) : 12738 - 12752
  • [6] Integrin αvβ6-TGFβ-SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer
    Bagati, Archis
    Kumar, Sushil
    Jiang, Peng
    Pyrdol, Jason
    Zou, Angela E.
    Godicelj, Anze
    Mathewson, Nathan D.
    Cartwright, Adam N. R.
    Cejas, Paloma
    Brown, Myles
    Giobbie-Hurder, Anita
    Dillon, Deborah
    Agudo, Judith
    Mittendorf, Elizabeth A.
    Liu, X. Shirley
    Wucherpfennig, Kai W.
    [J]. CANCER CELL, 2021, 39 (01) : 54 - +
  • [7] The tumor microenvironment at a glance
    Balkwill, Frances R.
    Capasso, Melania
    Hagemann, Thorsten
    [J]. JOURNAL OF CELL SCIENCE, 2012, 125 (23) : 5591 - 5596
  • [8] A NOVEL FUNCTION OF GLUTAMINE IN CELL-CULTURE - UTILIZATION OF GLUTAMINE FOR THE UPTAKE OF CYSTINE IN HUMAN-FIBROBLASTS
    BANNAI, S
    ISHII, T
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 1988, 137 (02) : 360 - 366
  • [9] Amino Acid Transporters in Cancer and Their Relevance to "Glutamine Addiction": Novel Targets for the Design of a New Class of Anticancer Drugs
    Bhutia, Yangzom D.
    Babu, Ellappan
    Ramachandran, Sabarish
    Ganapathy, Vadivel
    [J]. CANCER RESEARCH, 2015, 75 (09) : 1782 - 1788
  • [10] Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
    Bianchini, Giampaolo
    Balko, Justin M.
    Mayer, Ingrid A.
    Sanders, Melinda E.
    Gianni, Luca
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (11) : 674 - 690